Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

me period of 2013. For the six months ended June 30, 2014, net loss was $8.8 million, or $(0.28) on a fully diluted per share basis, compared to a net loss of $54.7 million, or $(4.35) on a fully diluted per basis for the same period in 2013. The lower loss on a per share basis in the three and six month periods ended June 30, 2014 compared to the same periods in 2013 are primarily due to a non-cash expense of $48.6 million related to the loss on the settlement of convertible notes that is reflected in the 2013 losses and the additional shares reflected in the 2014 per share calculations as a result of the Company's IPO in December 2013.

Cash balance totaled $66.2 million as of June 30, 2014, compared to $78.0 million on December 31, 2013.

Financial GuidanceBased on current operating plans, Xencor expects to have sufficient cash to fund research and development programs and operations through 2016, and maintains the 2014 year-end cash and cash equivalents estimate of approximately $54.0 million.

Conference Call and WebcastXencor will host a conference call today at 4:30 p.m. EDT to discuss these second quarter 2014 financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and providing the conference ID number 74824866. A live webcast of the conference call will be available online from the investor relations section of the Company's website at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.  
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor's
'/>"/>

SOURCE Xencor Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
3. Xencor, Inc. Announces Closing of Initial Public Offering
4. Pharmacyclics Reports Second Quarter 2014 Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
8. Endo Reports Second Quarter Financial Results
9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
11. Hospira Reports Second-Quarter 2014 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... VEGAS , March 26, 2015 Zimmer ... Vivacit-E ® Advanced Bearing Technology with ... A paper published earlier this month reported that, ... Vivacit-E Advanced Bearing Technology featuring Vitamin E ... maintained a significant wear rate reduction of 95 percent, ...
(Date:3/26/2015)... 26 mars 2015 Finesse Solutions annonce ... pour les innovateurs, visionnaires et cadres de direction ... d,une durée de deux jours proposée exclusivement sur ... le centre ville de San Francisco ... Il s,agira d,un forum destiné aux leaders des ...
(Date:3/26/2015)... Utah , March 26, 2015  Flexpoint Sensor ... with new customers it has received and shipped during ... get a lot of interest in the sensors for ... these sensors or have had custom sensors built for ... LLC who received custom sensors for medical rehab; a ...
Breaking Medicine Technology:Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3Finesse Solutions annonce l'événement Cellworld 2015 2Flexpoint Sensor Systems, Inc. Expands Customer Base with New Orders of Sensors 2
... and Non-Whites New to Antiretroviral Therapy Respond ... Similarly to ... treatment,regimens containing once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease ... (reducing the amount of HIV-1),and improving the immune system (increasing ...
... Tolerx, Inc., a,biopharmaceutical company engaged in the ... of immune-mediated diseases, announced today,that Genentech, a collaborator, ... anti-CD4 monoclonal antibody, into a phase 1 clinical ... is evaluating the,safety and tolerability of both single ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:3/26/2015)... Visiting Nurse Association of Northern New Jersey ... the Way, Brightening the Day, on Friday, May 1, ... Morristown, NJ. , Guests will enjoy an elegant ... delightful cuisine, an extensive silent auction and heart-warming testimony ... awards will be presented to this year’s honorees. ...
(Date:3/26/2015)... San Frencisco, CA (PRWEB) March 26, 2015 ... Implant Center are proud to announce expanded offerings for ... The San Francisco Dental Implant Center has long been ... efforts have expanded its offerings to meet the strong ... pride in our reputation as a top-rated dental implant ...
(Date:3/26/2015)... 2015 Innovative research and additional ... preventing often fatal ruptures, says The Bee Foundation, ... awareness of brain aneurysms and funding innovative research ... national attention with the death of longtime ... last Friday after suffering a ruptured brain aneurysm. ...
(Date:3/26/2015)... March 26, 2015 The National ... Assessment and Evaluation , has announced its partnership ... institutions, organizations, and corporations to accurately and securely ... learning. , Utilizing Questionmark’s state-of-the-art software and ... will offer improved delivery of the seventy-five to ...
(Date:3/26/2015)... Volunteers will collectively walk hundreds of miles ... funds to support the American Parkinson Disease Association’s ... the Cure. The Optimism Walk campaign is ... than 20 locations including, Boston, Chicago, Connecticut, Madison, Nashville, ... Seattle, St. Louis, New York, Nevada, South Florida, Vermont, ...
Breaking Medicine News(10 mins):Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 2Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 3Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2
... ... ... Wellness Center is now offering Kennedy Spinal Decompression Therapy to Springfield area residents suffering ... for lower back and neck pain sufferers., , ,Spinal Decompression Therapy has been clinically ...
... ... payroll processing time thus freeing staff to spend more time serving patients and less time ... ... improvement in staff productivity and payroll processing time thus freeing staff to spend more time ...
... ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to ... ... , , ... ...
... The Autism Consortium, an innovative research, clinical and family ... for families with autism spectrum disorders (ASDs), announced today ... testing methods for autism spectrum disorders is available from ... in their eFirst pages today and will appear in ...
... kind to date using cardiac computed tomography angiography, people ... artery disease are at higher risk of developing obstructive ... Ford Hospital researchers say. Researchers analyzed the data ... tomography angiography and found that those with a family ...
... ACL, meniscus at same time is one advance, ,Tommy John, ... Repairing a torn knee meniscus at the same time as ... children, a new study finds. , Meniscus cartilage acts as ... one of four major ligaments in the knee. , This ...
Cached Medicine News:Health News:Chiropractor Springfield, VA - Dr. Todd P. Sullivan Announces The Addition of Spinal Decompression Therapy 2Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 2Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 3Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2Health News:Strides Seen in Orthopedic Surgery for Kids 2
... 1 (IGF-1) is a polypeptide of 70 amino ... number of related insulin-like growth factors present in ... homology with proinsulin and has a number of ... growth hormone (GH) dependent to a high degree, ...
...
...
...
Medicine Products: